Louis Joseph Nisbet

Ernst & Young provides accounting services. Its services include auditing, accounting, tax and transaction services, assurance and advisory business, online transaction advisory and a wide range of financial services. The company was founded by Arthur Young and Alwin C. Ernst in 1881 and is headquartered in Kansas City, MO.

Singula Decisions Ltd. provides customer and revenue management software solutions and services. The company was founded by Jonathan Guthrie and Ronald Millar on May 22, 1997 and is headquartered in Kirkcaldy, the United Kingdom.

Part of Douterloigne Betonwerken, Beerse Betonhandel is a Belgian company that has a description related to depository banking functions not classified elsewhere. Beerse Betonhandel was acquired by Douterloigne Betonwerken on February 01, 1999.

Wood Mackenzie Ltd. provides research reports and consulting services for the global energy industry. The firm provides objective analysis and advice on assets, companies and markets. Its clients include international and national energy and metals companies as well as financial institutions and governments. The company was founded in May 1973 and is headquartered in Edinburgh, the United Kingdom.

ADEMTECH SA specializes in developing and manufacturing magnetic nanoparticles for diagnostic and scientific research applications. The firm produces magnetic nanoparticles for concentration, separation, purification, microfluidic device integration and identification of molecules and specific cells. The company was founded in 2000 and is headquartered in Pessac, France.

BPIFrance Investissement SAS (BPIfrance Investissement) is the private equity arm and subsidiary of State-owned Banque Publique d'Investissement in France. Formerly known as CDC Entreprises SAS, the firm was established in 1994 to carry out public-interest missions such as employment creation and momentum initiation in the private equity field. In 2013 they became BPIfrance Investissement when CDC Entreprises, FSI and FSI Régions merged. Headquartered in Paris, BPIfrance Investissement invests of behalf of the Government of France, as well as for third parties including FEI-Fonds Européen d'Investissement, BEI-Banque Européenne d'Investissement and BPCE SA. The firm invests directly or indirectly in SMEs and intermediate-sized companies at all stages of their development.

Janssen Pharmaceutica NV engages in the development of medical solutions. It offers research and development services in the field of mental illness, neurological disorders, anesthesia, analgesia, gastrointestinal disorders, fungal infection, allergies and cancer. The firms products include Zytiga, Caelyx, Dacogen, Edurant, Fentanyl-Janssen, Intelence, Leustatin, , Pariet, and Reminyl. The company was founded in 1953 by Paul Janssen and is headquartered in Beerse, Belgium.

Sunstone Capital A/S (Sunstone) is an independent venture capital firm headquartered in Copenhagen, Denmark. The firm was founded in 2007 by Peter Benson, Sten Verland, and Søren Lemonius, and invests on behalf of a group of institutional investors.

Aesica Formulation Development Ltd. develops pharmaceutical products. It offers sterile and nutraceutical product development and drug delivery services. The company was founded on December 22, 2005 and is headquartered in Northumberland, the United Kingdom.

Cizzle Biotechnology Ltd. develops therapeutic products for lung cancer. The firm promotes DNA replication and is involved in its organization and control. The company was founded by Dawn Coverley and Justin Ainscough in 2005 and is headquartered in York, the United Kingdom.

Opsona Therapeutics Ltd. operates as a immunology drug development company. It focuses on novel therapeutics and specializes in the prevention and treatment of solid organ transplantation, cancer, diabetes, autoimmune, inflammatory and Alzheimer’s diseases. The firm developed OPN-305, an antibody to reduce pro-inflammatory cytokine production, which is now at the clinical testing phase. The company was founded by Luke O'Neill, Kingston Mills and Dermot Kelleher in 2004 and is headquartered Dublin, Ireland.

Maven Capital Partners UK LLP (Maven Capital Partners) is a private equity subsidiary of Mattioli Woods PLC founded in 1986. The firm is headquartered in Manchester, United Kingdom.

BioCity Group Ltd (BioCity) is a venture capital firm founded in 2002. The firm is headquartered in London, United Kingdom.

Part of Mittera Group, Inc., Pioneer Graphics, Inc. is a commercial printing company. The company is based in Waterloo, IA. Pioneer Graphics was acquired by Colorfx LLC on November 11, 2015.

GlaxoSmithKline LLC engages in discovering, developing, and delivering medicines, vaccines, and other healthcare products. It offers prescription medicines that treat various diseases, including cancer, HIV/AIDS, depression, diabetes, high blood pressure, herpes, asthma, migraine, and heart diseases, as well as stomach and skin problems, infections, and flu. It also provides vaccines for children and adults; and over-the-counter products. The company was founded in 1929 and is headquartered in Philadelphia, PA.

Kurma Partners SA (KP) is an independent venture capital firm founded in 2009 by Thierry Laugel. The firm is headquartered in Paris, France.

Worldwide Business Development Corp. provides professional training and coaching services. The company is headquartered in Toronto, Canada.

XenoGesis Ltd. provides laboratory-based services to pharmaceutical clients. Its services include in vitro DMPK and pharmacology. PK, bioanalysis and metabolite identification, modelling and simulation, ADME packages, due diligence, and formulation service. The company was founded by Richard Weaver in 2011 and is headquartered in Nottingham, the United Kingdom.

Sygnature Discovery Ltd. engages in drug discovery activities. It specializes in target validation, hit identification, hit to lead, lead optimization, integrated drug discovery, and fragment based drug discovery. The company was founded by Simon Christopher Hirst in 2004 and is headquartered in Nottingham, United Kingdom.

GamaMabs Pharma SA specializes in developing monoclonal antibodies. It offers research and development solutions for biopharmaceutical industry. The company was founded by Jean-Francois Prost and Stephane Degove in June 2013 and is headquartered in Toulouse, France.

CorWave SA develops and manufactures blood pumps. The company was founded in 2011 and is headquartered in Paris, France.

Alderley Analytical Ltd. offers bespoke analytical services. It offers assay development and validation, sample analysis, Toxicokinetic and Pharmacokinetic Interpretation, reporting, consulting, and Biopharmaceuticals products. The company was founded by Elizabeth Thomas, Paul Holme, Claire Ayre, and Sally Hannam in 2013 and is headquartered in Alderly Edge, the United Kingdom.

Imcheck Therapeutics SAS operates as a biopharmaceutical company which develops immunotherapeutic anti-cancer strategies for research. The company was founded by Olive Daniel in 2015 and is headquartered in Marseille, France.

LimFlow SA develops and offers medical devices which transformes the treatment of critical limb Ischemi. The firm?s proprietary and CE marked technology is a novel and purely percutaneous therapy for ?no-option? CLI patients. The company was founded by Martin T. Rothman in 2012 and is headquartered in Paris, France.

Bio-Images Drug Delivery Ltd. develops and formulates modified and controlled release oral formulations. Its services include tablet-in-tablet drug delivery system under OralogiK technology, gamma scintigraphy, controlled release, generics development, clinical rescue, and microdosing. The company was founded by Howard Stevens and is headquartered in Glasgow, the United Kingdom.

Quorum Cyber Security Ltd. engages in secured a growth capital round. The company is headquartered in Edinburgh, the United Kingdom.

AlgoTherapeutix SAS is a clinical-stage biotechnology company based in Suresnes, France. The French company is focused on developing targeted, first-in-class therapeutics for peripheral neuropathic pain. Its lead asset, ATX01, is a proprietary topical formulation of amitriptyline that targets the signaling pathways involved in the regulation of pain by inhibiting specific nociceptive sodium channel receptors. The company is currently recruiting patients for a phase II clinical trial of 240 patients for chemotherapy-induced neuropathic pain and a phase II proof of concept trial for erythromelalgia. AlgoTherapeutix has secured FDA fast track development status and orphan drug designation in both the US and EU. AlgoTherapeutix has raised EUR 35 million to date and has a consortium of investors, including Relyens Innovation Santé/Turenne Capital, UI Investissement, and angel investors. The company was founded in 2018 by Olivier Jean Bohuon and Stéphane Thiroloix, with Stéphane Thiroloix serving as the CEO since 2018.